1. Name and Address of Reporting Person

Deschatelets Pascal

(C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM MA 02451)

2. Issuer Name and Ticker or Trading Symbol

Apellis Pharmaceuticals, Inc. [ APLS ]

3. Date of Earliest Transaction (Month/Day/Year)

08/08/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

X Director
10% Owner
X Officer (give title below)
Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Date of Transaction</th>
<th>Deemed Execution Date, if any</th>
<th>Transaction Code</th>
<th>Amount</th>
<th>Securities Acquired or Disposed Of (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Price</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/08/2022</td>
<td>M</td>
<td>18,500</td>
<td>A</td>
<td>$2.67</td>
<td></td>
<td>956,280</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/08/2022</td>
<td>S</td>
<td>12,000</td>
<td>D</td>
<td>$62.5</td>
<td></td>
<td>944,280</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Date Exercisable or Expiration Date (Month/Day/Year)</th>
<th>Title of Stock, Option, or Other Security Underlying Derivative Security (Instr. 3 and 4)</th>
<th>Amount or Number of Shares</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 6)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>08/08/2022</td>
<td>$2.67</td>
<td>M</td>
<td>18,500</td>
<td>12/05/2023</td>
<td>Common Stock</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. This is a scheduled exercise from 10B5-1 trading plan.
2. This stock option was granted on 12/5/2013 and is fully vested.

/s/ David Watson, attorney-in-fact for Pascal Deschatelets
08/09/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.